Signals
A new Lp(a) threshold could reshape cardiovascular risk assessment
Researchers have identified a lipoprotein(a) level above 175 nmol/L as a marker of substantially increased cardiovascular risk, strengthening the case for routine testing and future use of emerging Lp(a)-lowering therapies.
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
ASCO 2026: Are we overtreating cancer?
ASCO 2026: Why oncology is also paying attention to GLP-1 medicines
AI Pathology Moves From Demo to Workflow
AlphaGenome Makes Variant Interpretation Political
The AMR Pipeline Is Too Thin for the Threat Ahead
TB Diagnosis Moves Closer to the Patient
Hepatitis Elimination Is Still Losing Patients Before Diagnosis
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.